News

Published on 9 Jan 2025 on Zacks · via Yahoo Finance

Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?


Article preview image

Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on...

NASDAQ.HALO price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Halozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In Now

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we ...

Insider Monkey · via Yahoo Finance 12 Feb 2025

Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?

Investors in Halozyme Therapeutics, Inc. HALO need to pay close attention to the stock based on...

Zacks · via Yahoo Finance 9 Jan 2025

HALO Raises 2025 Financial Guidance, Keeps 2024 View, Stock Up

Shares of Halozyme Therapeutics, Inc. HALO were up 5% on Jan. 8 after the company raised its...

Zacks · via Yahoo Finance 9 Jan 2025

Zacks.com featured highlights include Leidos, Amazon.com, Halozyme Therapeutics...

LDOS, Amazon.com, Inc. AMZN, Halozyme Therapeutics, Inc. HALO and BioMarin Pharmaceutical Inc. BM...

Zacks · via Yahoo Finance 7 Jan 2025

HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Halozyme Therapeutics, Inc. HALO announced that it has withdrawn its non-binding proposal to acqu...

Zacks · via Yahoo Finance 25 Nov 2024

Halozyme Withdraws Bid to Purchase Drug Developer Evotec

Have a confidential tip for our reporters? Halozyme Therapeutics Inc. withdrew its bid to purchas...

Bloomberg 22 Nov 2024

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announc...

Benzinga · via Yahoo Finance 22 Nov 2024

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announc...

Benzinga · via AOL 22 Nov 2024

Halozyme says €2 billion takeover of Evotech would create leader in drug...

Halozyme says the combined company would have an estimated $2 billion in revenue in 2025.

Market Watch 18 Nov 2024

Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says

(Bloomberg) -- Halozyme Therapeutics Inc. plans to finance its €2 billion ($2.1 billion) proposed...

Bloomberg · via Yahoo Finance 17 Nov 2024